GLG Network Survey: Menopause Treatments

Please fill out the form to request access to the survey data

SURVEY DETAILS
TARGET POPULATION

GLG surveyed 70 gynaecologists across the US and Europe (UK, Italy, France, Germany and Spain).

What will you learn from this survey?

  • Respondents commented on diagnosis for menopause, common symptoms, patient journey, treatments prescribed, as well as discontinuation of treatments.
  • The research also looked into the treatment landscape, including treatments specifically asked for by patients, treatments preferred for severe symptoms and quick symptom relief, as well as prescription and effectiveness of non-pharmacological treatments.
  • Lastly, the survey captured a competitive assessment of menopause treatments on the basis of onset of therapeutic effect, degree of efficacy, overall patient experience and reimbursement/coverage.

Examples of findings:

  • Over nine-in-ten respondents agree that hot flashes (97%) and vaginal dryness/discomfort (91%) are among the most common menopause symptoms.
  • EstroGel (14%) is chosen as the top treatment for severe menopause symptoms, while Activella (13%) is preferred for quick symptom relief.
  • Although yoga and relaxation/meditation are prescribed by over half (54%) of respondents as a non-pharmacological treatment, their effectiveness is well below other treatments.

Deliverables

The GLG Surveys team drafted the questionnaire with the support of GLG Network Member, Raksha Joshi, OBGYN & Director of Women’s Health and Director of Quality and Performance Improvement, at VNA of Central Jersey and VNA health group.

  • 1 x Individual responses (“raw data”) in Excel.
  • 1 x PPT report with aggregated data.
  • Executive summary with key takeaways and highlights from the raw data.

Sample Questions

  • Which of the following are a part of your patient’s journey after diagnosis?
  • Do you perform/order any laboratory tests to confirm your diagnosis of your patient’s symptoms?
  • Which of the following menopausal treatments have your patients specifically asked for?
  • Which of the following is your most preferred choice of treatment for patients who ask for quick symptom relief?
  • Please rank the following treatments in terms of overall patient experience, where rank 1 is the treatment with the best patient experience.
  • Are you aware of any non-hormonal medications which are in development of Vasomotor Symptoms of Menopause (VSM)?
  • Please rate the following non-pharmacological treatments on the basis of therapeutic effect.

Access

This survey is available to subscribers of the Healthcare (HC) sector (Limited subscriptions and above). This offer includes the raw data file and a high-level presentation through PowerPoint. Please contact your GLG representative for details on your firm’s access.

DISCLAIMER

Please be advised that GLG Network Surveys operate differently than traditional GLG consultations, surveys, teleconferences, etc. and it is advisable that you consult with your firm’s legal and/or compliance department to review your use of the product and the payment for such work under your current subscription. 

By downloading this document and/or participating in the Network Survey, you understand and agree that the information and material provided by GLG, including survey results and survey proposal information, is provided for your own insight and informational purposes only. You further acknowledge and agree that this is a Network Survey for multiple GLG clients, and the results will be provided to all GLG clients that agree to participate in the Network Survey and GLG clients that agree to purchase the Survey results in the future. All survey results do not constitute investment advice or a recommendation. In using this Survey, you agree to hold Gerson Lehrman Group and the Survey respondents harmless and free of all liability as a result of your use of this Network Survey, other than liability resulting from the gross negligence or wilful misconduct of the protected party. You otherwise agree to be bound by Gerson Lehrman Group’s Usage Policies in your interactions with Gerson Lehrman Group and your receipt of services. These Survey results are for are for client’s own use and client shall not redistribute, disseminate, publish, or display the same, in whole or in part, to any third parties or publicly without the prior written permission of Gerson Lehrman Group, except explicitly set forth in your agreement with GLG. This survey will be double-blinded to both client and respondent. GLG reserves the right to restrict the number of clients that can pre-commit access. These Network Surveys are priced outside of standard GLG subscriptions but at a substantially reduced price to commissioning a fully proprietary GLG Network Survey. Upon finding these terms acceptable, please send an affirmative confirmation via email, which GLG will file in its records. Once confirmed, please note that the Client’s agreement to purchase the Network Survey is a legally binding and irrevocable commitment. If the survey is not included within your subscription, GLG will invoice Client for the fees due for the Network Survey. Please note that some respondents may not be Network Members, and the Terms and Conditions of Network Membership would not apply to such respondents and detailed records for them will not be available aside from the information that GLG capture in the Network Survey.